Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
- Citation:
- Blood Adv vol 5 (13) 2775-2787
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- collection
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 607
- Children:
- None
- Pharmas:
- Deltec Inc
- Grants:
- U10CA180821, U10CA180882, UG1CA233338, U24CA196171, P30CA033572, UG1CA233180, UG1CA233191, UG1CA233327, UG1CA233331, UG1CA233339, UG1CA189848, UG1CA189850, UG1CA189858
- Corr. Author:
- Authors:
- Alison R. Walker Guido Marcucci Jun Yin William Blum Wendy Stock Jessica Kohlschmidt Krzysztof Mrózek Andrew J. Carroll Ann-Kathrin Eisfeld Eunice S. Wang Sawyer Jacobson Jonathan E. Kolitz Mohan Thakuri Grerk Sutamtewagul Ravi Vij Robert K. Stuart John C. Byrd Clara D. Bloomfield Richard M. Stone Richard A. Larson
- Networks:
- CA043, IA018, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY158, LAPS-OH007, MUSC, NC031, NORTHWELL, OH070
- Study
- CALGB-10201
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- 20, 25, Clinical Trials and Observations